Reinsurance Group of America 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- RGA reported pretax adjusted operating income of $736 million for the quarter, or $8.49 per share after tax, and a trailing-12-month adjusted operating return on equity of 19.1%, excluding AOCI and notable items.
- Management cited strong investment performance, favorable economic claims experience, and positive results from in-force actions as key contributors to the quarter.
- Total premiums excluding PRT grew 8.9% year-to-date, or 8.2% constant currency.
- Economic claims were $67 million better than expectations, while the financial impact was a negative $9 million; economic claims have run favorable by over $400 million since 2023.
- The annual actuarial assumption review had no net impact on quarterly pretax adjusted operating income and is expected to have a de minimis impact on the go-forward earnings run rate.
- The core portfolio yield, excluding VII, was 4.96%, and the new money rate was 6.31%; Q3 impairments and changes in allowances were $71 million.
- Annualized VII returns were approximately 15% for the quarter and approximately 12% year-to-date, compared with a long-term expectations range of 10% to 12% and a 7% planned return for 2026.
- RGA deployed $119 million into in-force transactions and returned $139 million to shareholders, including $75 million in share repurchases and $64 million in dividends; year-to-date buybacks totaled $175 million.
- RGA ended the quarter with approximately $1.8 billion of excess capital, after using $400 million to retire a senior security, and book value per share excluding AOCI and B36 effects was $178.59.
- The U.S. completed 4 pension risk transfer transactions totaling over $800 million in combined premium; EMEA completed transactions in the U.K. and continental Europe, and APAC closed several flow deals, notably in Hong Kong and Japan.
- Ruby Re's capital was fully deployed during the quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to RGA's third quarter 2026 earnings call. Participants have been placed on a listen-only mode. Your lines will be open for questions following the presentation. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's prepared remarks, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then two. Today's call is being recorded. If you have any objections, you may disconnect at this time. Some of the comments made during this conference call, including answers given in response to questions, may constitute forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
For more detail on the risks and uncertainties, please refer to the risk factors discussed in RGA's periodic reports to the SEC. For reconciliation of the non-GAAP measures discussed on this call, as well as other information regarding these measures, please refer to the earnings release and other materials in the investor relations section of the company's website. There will be references to the earning presentation slides throughout the call. I will now turn the floor over to Tony Cheng for his opening remarks.
Good morning, everyone, and thank you for joining us today. We appreciate your continued interest in RGA. I am pleased to share that we delivered excellent results this quarter, with strong performance across all regions. Investment performance was robust, and economic claims experience was favorable to expectations, demonstrating our success on both sides of the balance sheet. These results were another proof point on the importance of our strategy and core differentiators: deep biometric expertise, strong asset management capabilities, a global platform of local offices, a market-leading brand, and flexibility to partner across the industries. They also demonstrate our ability to generate attractive risk-adjusted returns across a range of market environments. With this strong foundation in place, our priorities moving forward remain clear: deliver attractive, sustainable returns, manage risk well, and deploy capital where we see the best long-term value.
Before I turn to the results, let me highlight three items from the quarter and how they tie to our strategy. First, our pipeline for both in-force and flow business remains attractive. This quarter, the U.S. PRT and U.K. longevity markets picked up after a slow start to the year. We were active in both, completing several transactions, and we are encouraged by the outlook for the fourth quarter and into 2027. Beyond these two markets, our other business segments continue to benefit from attractive opportunities, building on our strong market presence. Second, a key element of our biometric risk expertise is the rigor of our assumption-setting process. This quarter, we completed our annual assumption review. This resulted in no net impact on consolidated pre-tax adjusted operating income. The completion of the review gives us added confidence in both our in-force business and the new business we are writing.
Finally, third-party capital remains a core element of our capital management strategy. These structures provide an opportunity for third-party investors to participate in the returns of our business while generating incremental fee income over time and enhancing our flexibility to fund growth and return capital to shareholders. In the quarter, I am very pleased that we showed the continued execution of this strategy with the full deployment of Ruby Re capital. Turning now to the regional results. In the Americas, the results for the quarter were driven by strong investment income, sound underwriting experience, and the continued favorable impact of in-force actions executed in prior periods. New business momentum continued, and we were particularly pleased with the completion of four pension risk transfer transactions totaling over $800 million in combined premium.
The overall pipeline for the region is encouraging, and we are seeing a wide range of opportunities across the spectrum of underwriting, product development, and asset-intensive transactions with biometric risk. In EMEA, earnings outperformed our expectations, benefiting from favorable claims experience and higher investment income. After a slower start to the year, largely due to a quiet U.K. longevity market, we have now completed a number of transactions in this core growth area, covering lives in both the U.K. and continental Europe. We are also encouraged by the momentum we are seeing in the market and in our pipeline. Asia Pacific delivered another strong quarter, driven by the earnings contribution from recent new business and strong investment income. Leading with biometric expertise, local experience, and long-standing client relationships, we closed several flow deals in the region, notably in Hong Kong and Japan.
These deals were in our sweet spot, leveraging both sides of the balance sheet and showcased the expertise of our exceptional local teams. Our ability to deploy capital across all our regions and a range of products gives us a significant advantage. Just as important, we remain selective, maintaining discipline in pricing, underwriting, and capital deployment. Let me emphasize that our capital deployment into in-force transactions and flow business this year has been focused on exclusive arrangements with attractive risk-adjusted returns, and we are very pleased with the high-quality nature of this business. Taking a step back, what connects these results to our strategy are our strengths in four key areas. First, win-win transactions. We pursue transactions that deliver strong returns for RGA and real benefits for our clients. Our five decades of experience, global presence, and local market knowledge let us focus where we are best positioned.
We focus on both sides of the balance sheet, pairing deep biometric expertise with diversified investment capabilities. Second, scaling our global platform. Demand for risk and capital solutions continue to grow, and our strong balance sheet and global brand make us a trusted counterparty. Third, optimizing our balance sheet. We do this through in-force management, improved risk-adjusted investment returns, and both internal and third-party sources of capital. Finally, disciplined capital stewardship. We balance investing in attractive opportunities with returning capital to shareholders. Here are some examples from this quarter of how we are putting this approach to work around the world. In the U.S., our underwriting capabilities continue to set us apart. Case volumes remain significantly above prior year levels. Our strategic underwriting program accounted for almost half of this quarter's cases and is the largest source of growth in our underwriting products.
These programs will further entrench our strategic partnership with the client, including new product development, creating exclusive business that is very durable. In Asia, our underwriting and product development capabilities supported client wins across the region. In Japan, we supported the launch of a simplified underwriting mortality product for the corporate-owned life market. In Hong Kong, one of our embedded digital underwriting capabilities was highlighted by a client for its role in accelerating medical underwriting decisions, widening consumer access to cover, and improving the new business experience. In India, our electronic underwriting system has moved into early client development with one client now live and another implementation progressing well. Just like in the U.S., expanding our underwriting capabilities allows us to help clients reach more clients, more customers, and make more better-informed risk decisions.
That deeper partnership is a differentiator for RGA and helps us continue to grow in these key markets. Turning to capital allocation, we have deployed $119 million into in-force transactions in the quarter, and we returned $139 million to shareholders, including $75 million in share repurchases and $64 million of dividends. We maintained a strong balance sheet, ending the quarter with $1.8 billion of excess capital. Balanced use of excess capital is a key part of how we build long-term shareholder value. As we look ahead, our fundamentals remain strong, and our pipeline for both in-force and flow business is healthy. Our confidence in 2026 and beyond remains high. Our advantages are durable, and our strategy builds on a proven track record of creating long-term value for our shareholders.
We are confident we will meet or exceed our intermediate-term financial targets and continue to deliver long-term value for our shareholders. Before I close, I would like to recognize Jonathan Porter, who plans to retire in early 2027. I congratulate Jonathan on a successful career and thank him for the lasting impact he has made at RGA. On a personal note, Jonathan has been an invaluable partner to me and to many leaders across RGA. I am grateful for his many contributions and excited for him as he begins this well-deserved next chapter. Following a thorough search, we are pleased to announce that Meyrick Douglas will join RGA in the fourth quarter and take over as Chief Risk Officer on January 1, 2027. Meyrick brings decades of leadership experience spanning all aspects of the risk function, most recently at Prudential and Morgan Stanley.
He and Jonathan will have the opportunity to work closely during a transitional period. With that, I will turn the call over to Laura to share her comments on the quarter.
Thanks, Tony, and good morning, everyone. Turning to the results, RGA earned pre-tax adjusted operating income of $736 million for the quarter, or $8.49 per share after tax. Over the trailing 12 months, our adjusted operating return on equity was 19.1%, excluding AOCI and notable items. This was another excellent quarter for us, built on disciplined execution across our businesses. Numerous items contributed to the strong results. First, investment results were excellent, as our variable investment income and new money rate were very strong. Second, all regions performed well, demonstrating the breadth and depth of our earnings platform. And third, in-force actions delivered positive results, highlighting the value of the work we are doing to optimize our balance sheet.
This quarter is another proof point that we are using our strategic advantages to deliver consistent, strong results, which gives us confidence in meeting or exceeding our targets. Now to the segment results. In the U.S. and Latin America, traditional results reflected strong variable investment income and the favorable impacts of cumulative in-force actions executed over time, and individual mortality experience was in line with expectations on both an economic and financial basis. Financial Solutions results were favorable primarily due to VII. In Canada, traditional earnings reflected favorable experience on individual life business, and Financial Solutions earnings were favorable due to strong VII. In EMEA, traditional results reflected favorable claims experience, and Financial Solutions results reflected higher investment income and favorable one-time items. In APAC, traditional results reflected a modestly unfavorable financial impact from claims, although economic claims experience was favorable, and Financial Solutions results reflected strong variable investment income.
Finally, our corporate and other segment reported an adjusted operating loss before tax of $22 million. This was better than our expectations, primarily due, again, to strong VII. I'll now turn to the notable items in the quarter related to our annual review of actuarial assumptions. At the consolidated level, the review had no net impact on pre-tax adjusted operating income for the quarter and is expected to have a de minimis impact on our go-forward earnings run rate. At the segment and business line level, the impacts were modest, with favorable and unfavorable items largely offset across the regions. We are pleased with this result, as it reconfirms our long-term pricing and modeling assumptions across the regions and the products. Now turning to premium growth. Total premiums, excluding PRT year-to-date, grew 8.9% or 8.2% constant currency, which reflects our strong business momentum.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
